Paragastric Autonomic Blockade to Prevent Visceral Pain After Laparoscopic Sleeve Gastrectomy (PG-ANB)

April 27, 2022 updated by: Yaneth Herazo Beltran, Universidad Simón Bolívar

Paragastric Lesser Omentum Neural Block to Prevent Visceral Pain After Laparoscopic Sleeve Gastrectomy: A Randomized Clinical Trial Protocol.

Visceral pain (VP) following laparoscopic sleeve gastrectomy remains a substantial problem. VP is associated with autonomic symptoms, especially nausea and vomiting, and is unresponsive to traditional pain management algorithms aimed at alleviating somatic (incisional) pain. The present study was performed to evaluate the safety and effectiveness of laparoscopic paragastric autonomic neural blockade (PG-ANB) in managing the symptoms associated with VP following sleeve gastrectomy.

Study Overview

Detailed Description

Introduction Although seldom discussed, visceral pain (VP) is the most significant source of pain in the first 24 hours following laparoscopic sleeve gastrectomy (LSG) and other laparoscopic procedures (1). The somatic pain induced by surgical trauma to the abdominal wall after LSG is effectively managed using conventional analgesia and transversus abdominis plane (TAP) blocks (2-4). In contrast, the visceral, colicky pain patients experience after LSG does not respond well to traditional pain management regimens. During the last 15 years at our institutions, we have used many analgesic strategies to manage these burdensome symptoms in more than 2000 LSG procedures. Despite these efforts, no analgesic strategies have been satisfactorily effective (5,8,9).

Autonomic nerve blocks have been described in the pain management literature. Specifically, celiac ganglia blocks have been reported in managing chronic pain caused by foregut malignancies or pancreatitis (11,12). In these patients, neuraxial blocks have been demonstrated to be safe and effective methods of chronic pain management. To our knowledge, however, paragastric autonomic neural blockade (PG-ANB) has not been performed as part of perioperative multimodal pain management algorithms in gastrointestinal surgery. The two proposed main mechanisms of action of this autonomic blockade are a reduction in the parasympathetic influence over the stomach, which reverses its increased muscular tone and deactivates mechanosensitive receptors in the organ wall, and blockade of the afferent sympathetic fibers that convey VP to the spinal cord (13).

In a pilot observational study involving 35 patients, we observed improvement in the severity of VP in the epigastric and retrosternal areas as well as improvement in associated autonomic symptoms following PG-ANB (14). The effect was most pronounced during the immediate postoperative period but persisted until discharge. Analgesic requirements and the presence of nausea and vomiting were also reduced. The current study was performed to further validate these preliminary findings through a randomized, double-blinded controlled trial.

Study design This prospective, double-blinded, randomized clinical trial involved patients undergoing laparoscopic sleeve gastrectomy at two high-volume institutions. The patients were randomized to laparoscopic transversus abdominis plane block with or without PG-ANB.

Sample size Previously published data have indicated that differences of 1 to 2 points on an 11-point visual analog pain scale are clinically significant (15-17). Based on these prior studies, we chose a difference of 1 point as the minimum clinically significant difference for sample size calculation and assumed a standard deviation of 2 points. With a p-value of 0.05 and a power of 0.80, we estimated that a total of 128 patients would need to be enrolled in this study. To allow for any potential loss to follow-up, we enrolled 150 patients in the study.

Randomization and blinding Randomization was performed using sealed envelopes prepared by the data manager and stratified by institution in blocks of six. The data manager stored the randomization list containing the final treatment assignments. Only the data manager had access to the randomization list throughout the study. These sealed envelopes were placed in the patients' charts and could not be opened until the patient was in the operating room under general anesthesia. At that point, the surgeon became cognizant of the procedure to perform but did not participate in assessing the patient or collecting data. Both the patient and the investigator assessing the patient were blinded to the treatment arm assignments. The investigator evaluated the patients for vital signs, pain scores, autonomic symptoms, and analgesic requirements and recorded the information.

Data collection The patients' age, sex, body mass index, current medications, and medical and surgical history were prospectively recorded at the preoperative clinic visit during study enrollment with informed consent. An analog pain scale survey was administered by an investigator blinded to the patients' groups at 1 hour postoperatively (in the recovery room), 8 hours postoperatively, and the following morning. The investigator recorded the need for analgesics; the presence of nausea, vomiting, retching, excessive salivation, hiccups; and vital signs.

Statistical analysis Continuous outcome variables were compared with two-sample t-tests. Categorical and binary outcome variables were compared using chi-squared tests. Patient-reported pain scores were further compared using linear regression with the surgeon who operated and the location of the procedure as covariates to assess the effect of the surgeon and location on the primary outcome.

Postoperative recovery protocol All patients received proton pump inhibitors, conventional antiemetics, and a scheduled baseline analgesic such as acetaminophen (1 g intravenously every 6 hours) or dipyrone (1 g intravenously every 6 hours). The first-line rescue analgesic was a nonsteroidal anti-inflammatory drug such as diclofenac (intravenously every 12 hours) together with hyoscine butylbromide (0.2 mg intravenously every 12 hours), and the second-line rescue analgesic was tramadol (1 mg per ideal body weight intravenously every 6 hours). Tramadol was the only opioid derivative used. A popsicle was offered the afternoon after surgery, and clear fluids were started the following day. Patients were discharged from the hospital at noon the day after surgery.

Study Type

Interventional

Enrollment (Actual)

145

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Atlantico
      • Barranquilla, Atlantico, Colombia, 081007
        • Clinica Portoazul

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

Adult patients who were scheduled for LSG at each participating institution from 25 August 2021 to 8 February 2022 and consented to study participation.

Exclusion Criteria:

  • the exclusion criteria were an age of <18 years.
  • the performance of concomitant procedures in addition to LSG.
  • allergies to medications included in the postoperative management protocol.
  • anesthetic complications related to the LSG that would alter the postoperative management protocol.
  • surgical complications related to the LSG that would alter the postoperative management protocol.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: PG-ANB Block
The paragastric lesser omentum neural block is performed with a 25-gauge needle attached to a venous catheter extension introduced through the left 12-mm port. The needle is capped during its introduction, and the cap is removed inside the abdomen using a grasper and kept under direct vision. Infiltration of 20 mL of non-diluted 0.5% bupivacaine is performed at six levels with careful aspiration preceding fluid infiltration. Four of the areas are next to the vagus nerves and branches, and two are in the vicinity of the common hepatic and left gastric arteries
Paragastric autonomic neural blockade with Bupivacaine
Other Names:
  • Laparoscopic transverses abdomens plane (TAP) block (To Both the control and experimental arms)
  • Laparoscopic sleeve gastrectomy(LSG) to all patients
No Intervention: Control
No paragastric neural block is performed in the control group. The same standard analgesic protocol consisting of acetaminophen (1 g) and morphine (3-5 mg) is used in all patients before extubation and TAP block is performed in both groups (control and experimental)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The patient-reported pain scores using an 11-point visual analog scale for pain( 11 being the worse pain).
Time Frame: Outcomes were assessed up to 24 hours after surgery during the period of inpatient admission following LSG.
An analog pain scale survey was administered by an investigator blinded to the patients' groups at 1 hour postoperatively (in the recovery room), 8 hours postoperatively, and the following morning
Outcomes were assessed up to 24 hours after surgery during the period of inpatient admission following LSG.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The secondary outcomes were analgesic requirements.
Time Frame: The recorded administered doses of analgesics were assessed up 24 hours after surgery during the period of inpatient admission following LSG.
The investigator recorded the need for additional doses of the analgesics, established in the protocol, at one, eight and twenty four hours after surgery.
The recorded administered doses of analgesics were assessed up 24 hours after surgery during the period of inpatient admission following LSG.
The secondary outcome was present of nauseas
Time Frame: Recorded up to 24 hours after surgery
The investigator recorded the present of nausea at 1, 8 and 24 hours after surgery.
Recorded up to 24 hours after surgery
The secondary outcome was present of vomiting
Time Frame: Recorded up to 24 hours after surgery
The investigator recorded the present of vomiting at 1, 8 and 24 hours after surgery.
Recorded up to 24 hours after surgery
The secondary outcome was present of retching
Time Frame: Recorded up to 24 hours after surgery
The investigator recorded the present of retching at 1, 8 and 24 hours after surgery.
Recorded up to 24 hours after surgery
The secondary outcome was present of excessive salivation
Time Frame: Recorded up to 24 hours after surgery
The investigator recorded the present of excessive salivation at 1, 8 and 24 hours after surgery.
Recorded up to 24 hours after surgery
The secondary outcome was present of hiccups
Time Frame: Recorded up to 24 hours after surgery
The investigator recorded the present of hiccups at 1, 8 and 24 hours after surgery.
Recorded up to 24 hours after surgery
The secondary outcomes was the mean arterial blood pressure
Time Frame: Recorded at 10 minutes after blockade
The investigator recorded the mean arterial blood pressure 10 minutes after blockade.
Recorded at 10 minutes after blockade
The secondary outcomes was the median heart rate
Time Frame: Recorded at 10 minutes after blockade.
The investigator recorded the median heart rate 10 minutes after blockade.
Recorded at 10 minutes after blockade.
The secondary outcomes was the mean arterial blood pressure.
Time Frame: Recorded up to 24 hours after surgery
The investigator recorded the mean arterial blood pressure at 1, 8 and 24 hours after surgery.
Recorded up to 24 hours after surgery
The secondary outcomes was the median heart rate.
Time Frame: Recorded up to 24 hours after surgery
The investigator recorded the median heart rate at 1, 8 and 24 hours after surgery.
Recorded up to 24 hours after surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Jorge Daes, MD FACS, Academic Director Clinica portoazul, Barranquilla, Colombia

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 13, 2021

Primary Completion (Actual)

February 3, 2022

Study Completion (Actual)

March 21, 2022

Study Registration Dates

First Submitted

April 16, 2022

First Submitted That Met QC Criteria

April 27, 2022

First Posted (Actual)

April 29, 2022

Study Record Updates

Last Update Posted (Actual)

April 29, 2022

Last Update Submitted That Met QC Criteria

April 27, 2022

Last Verified

April 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pain, Postoperative

Clinical Trials on Paragastric autonomic neural blockade

Subscribe